Hamidovic received a PharmD from the University of Wisconsin in 2002 and an MS in Clinical Investigation from Northwestern University in 2007.

Research Interests

Hamidovic’s research focuses on developing novel pharmacological treatments for smoking cessation. Her Clinical and Experimental Drug Addiction Research Lab evaluates intranasal insulin for its efficacy in reducing cravings, improving cognitive function and reducing snack intake during smoking cessation. The lab actively uses tests of memory and cognition, eating behavior, stress reactivity and metabolic processing to analyze efficacy of CNS insulin in increasing smoking abstinence rates. Clinical measures collected in the lab include safety assessments of endocrine and olfactory neurological parameters. She holds two Investigational New Drug Approvals by the FDA to evaluate novel pharmacological approaches for smoking cessation.